| human | Q5 |
| P6178 | Dimensions author ID | 01000566750.30 |
| P496 | ORCID iD | 0000-0001-8297-7971 |
| P1153 | Scopus author ID | 7403605083 |
| P734 | family name | Schwartz | Q2253414 |
| Schwartz | Q2253414 | ||
| Schwartz | Q2253414 | ||
| P106 | occupation | researcher | Q1650915 |
| Q33614436 | A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study. |
| Q38871635 | A novel bio-functional material based on mammalian cell aggresomes. |
| Q52581254 | AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. |
| Q71530615 | Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis |
| Q38345083 | Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. |
| Q58965246 | BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency |
| Q57200503 | BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes |
| Q38998656 | Biological assessment of self-assembled polymeric micelles for pulmonary administration of insulin. |
| Q35749872 | Brush border myosin Ia has tumor suppressor activity in the intestine. |
| Q41467332 | CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation. |
| Q38702970 | Cancer stem cells and personalized cancer nanomedicine. |
| Q41828664 | Cloning and characterization of CD300d, a novel member of the human CD300 family of immune receptors. |
| Q38867144 | Diosgenin-based thio(seleno)ureas and triazolyl glycoconjugates as hybrid drugs. Antioxidant and antiproliferative profile. |
| Q58577525 | Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells |
| Q38331785 | EMT blockage strategies: Targeting Akt dependent mechanisms for breast cancer metastatic behaviour modulation |
| Q37170873 | EPH receptors in cancer. |
| Q40230554 | EPHB4 and survival of colorectal cancer patients. |
| Q103787359 | Extracellular Vesicles as Drug Delivery Systems in Cancer |
| Q38846958 | Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells |
| Q57978027 | Frameshift mutations in Fas, Apaf-1 and Bcl-10 in gastro-intestinal cancer of the microsatellite mutator phenotype |
| Q58966488 | Frequent ki-ras mutations in gastric tumors of the MSI phenotype |
| Q77901849 | Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis |
| Q39422372 | Generation and characterization of orthotopic murine models for endometrial cancer. |
| Q57882192 | Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families |
| Q54593908 | High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. |
| Q52945664 | Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. |
| Q36481765 | Human SMC2 protein, a core subunit of human condensin complex, is a novel transcriptional target of the WNT signaling pathway and a new therapeutic target. |
| Q89879117 | Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells |
| Q38975701 | Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles |
| Q58966086 | KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression |
| Q46803723 | Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. |
| Q83189100 | Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells |
| Q35880786 | Myo5b knockout mice as a model of microvillus inclusion disease. |
| Q24545763 | Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT |
| Q104466549 | Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease |
| Q74557246 | Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR |
| Q43725407 | Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. |
| Q38140915 | PAR-5 is a PARty hub in the germline: Multitask proteins in development and disease. |
| Q77995576 | Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer |
| Q71782209 | Promoter demethylation in MMTV/N-rasN transgenic mice required for transgene expression and tumorigenesis |
| Q34628925 | RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. |
| Q57567752 | SMAD4 as a Prognostic Marker in Colorectal Cancer |
| Q34410598 | SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. |
| Q38795861 | Self-assembly PEGylation assists SLN-paclitaxel delivery inducing cancer cell apoptosis upon internalization. |
| Q39777927 | Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. |
| Q57567652 | Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis |
| Q57978019 | Somatic mutations in mitochondrial DNA do not associate with nuclear microsatellite instability in gastrointestinal cancer |
| Q53330772 | Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. |
| Q39506785 | Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. |
| Q53186092 | The 14-3-3 gene par-5 is required for germline development and DNA damage response in Caenorhabditis elegans. |
| Q89783436 | The Biological Potential Hidden in Inclusion Bodies |
| Q35618771 | The Receptor CMRF35-Like Molecule-1 (CLM-1) Enhances the Production of LPS-Induced Pro-Inflammatory Mediators during Microglial Activation. |
| Q39801979 | The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. |
| Q40014673 | Transforming pathways unleashed by a HDAC2 mutation in human cancer. |
| Q38044091 | Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. |
| Q50255169 | α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration |
Search more.